Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia. (ALBUCAP)
Effect of Albumin Administration on Outcomes in Hypoalbuminemic Patients Hospitalized With Community-acquired Pneumonia (ALBUCAP): a Prospective, Randomized, Phase III Clinical Controlled Trial.
Sponsor: Institut d'Investigació Biomèdica de Bellvitge
Terminated
Low recruitment
Other terminated trials from Institut d'Investigació Biomèdica de Bellvitge
See all terminations from Institut d'Investigació Biomèdica de Bellvitge
Other Community-acquired Pneumonia trials with similar outcome
Listed as NCT04071041, this PHASE3 trial focuses on Community-acquired Pneumonia and Hypoalbuminemia and remains terminated or withdrawn. Sponsored by Institut d'Investigació Biomèdica de Bellvitge, it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Unknown Status → Terminated
-
Nov 2022 — Feb 2023 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Dec 2019 — Apr 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Institut d'Investigació Biomèdica de Bellvitge
- Instituto de Salud Carlos III
- Jordi Carratala
For direct contact, visit the study record on ClinicalTrials.gov .